Alpha Teknova, Inc.TKNO

Alpha Teknova, Inc. sells catalog and custom reagents to pharmaceutical, biotech, CDMO, diagnostic, academic and government customers, with revenue recognised when control of goods transfers to the customer. The company’s latest 10-Q for the quarter ending 31 March 2026 shows net income of negative $4.6 million on revenue of $11.1 million, a net margin of roughly negative forty-one percent. Operating income was negative $4.3 million, and operating cash flow was negative $3.4 million, all figures that would prompt polite applause at a business-plan competition and arched eyebrows in a management desks.

Teknova’s product catalogue spans microbial culture media, buffers, agar plates, cryopreservation systems (including the PluriFreeze line co-developed with Pluristyx for allogeneic cell therapy), and custom manufacturing through Express-Tek Production, which promises turnaround in days via pre-ordered raw materials and prioritised queues. The company’s website highlights neat rows of branded bottles and an ‘AAV-Tek Solutions’ image, as if shelf appeal compensates for a cash-burning business model. Teknova states it stocks over 1,400 ready-to-ship products and promises industry-leading turnaround for custom solutions from discovery to commercialisation, but the 10-Q shows inventory of $6.9 million, up only $233,000 in the quarter.

Cash and cash equivalents were $4.3 million at 31 March 2026, with $13.5 million in short-term investments, stockholders’ equity of $64.9 million, and liabilities of $33.7 million. The company spent $221,000 on property, plant and equipment, incurred $609,000 in research and development, and reported diluted weighted-average shares outstanding of 53.6 million with a diluted loss per share of $0.08. The 10-Q also notes that customers accounting for 10% or more of revenue and accounts receivable were present, a disclosure that usually accompanies concentration risk without naming the customers in the filing itself.

Teknova’s SEC filings are available via its EDGAR index and company facts JSON, with the latest 10-Q filed on 7 May 2026. The company is listed on a US exchange, and the SEC filings provide the primary source of operating and financial data; no regional exchange or non-US filings are cited. The evidence does not include analyst estimates, valuation commentary, or trading volumes, so these are not part of this report.

There is no evidence in the sourced pack of any material customer wins, regulatory approvals, or new product launches during the review period; the only concrete product developments are the continuing availability of PluriFreeze media and the Express-Tek Production service, both already disclosed on the company’s product pages. The cash burn and negative operating cash flow raise questions about the sustainability of the current operating model absent a material acceleration in revenue growth or a reduction in cash outflows. Evidence that would materially change the file would include a 10-Q or 8-K disclosing a new material customer contract, a shift to positive operating cash flow, or a capital raise, none of which are present in the supplied sources.